Journal: PLoS ONE

Article Title: Wogonin Has Multiple Anti-Cancer Effects by Regulating c-Myc/SKP2/Fbw7α and HDAC1/HDAC2 Pathways and Inducing Apoptosis in Human Lung Adenocarcinoma Cell Line A549

doi: 10.1371/journal.pone.0079201

Figure Lengend Snippet: (A) Analysis of the mitochondrial membrane potential (ΔΨm) using JC-1 staining after exposure to wogonin for 48 h. A fluorescence microscope was used to visualize the results. Mitochondrial depolarization was indicated by an increase in green fluorescence and a decrease in red fluorescence intensity. (B) Protein levels of Bcl-2, Mcl-1, XIAP, survivin and PARP assayed by western blot. (C) Cytoplasmic proteins were extracted for western blot analysis of released Cytochrome c and AIF. In these experiments, cells were exposed to wogonin 0, 15, 25, 35 µg/mL for 48 h. * P <0.05 vs control group, ** P <0.01 vs control group.

Article Snippet: The following antibodies were used: Fbw7(Cdc4, H-300) and p-c-Myc (Thr 58) (Santa Cruz, USA); c-Myc, GSK3β, AIF (apoptosis inducing factor, Proteintech Group, Inc., USA); HDAC1, HDAC2, Skp2, Survivin, Bcl-2 (B-cell lymphoma 2), β-Actin (Boster, China); Mcl-1 (myeloid cell leukemia sequence 1), XIAP(X-linked inhibitor of apoptosis protein, Bioss, China); Cytochome c (KeyGEN, China); PARP (poly ADP-ribose polymerase, Sino Biological Inc., China).

Techniques: Staining, Fluorescence, Microscopy, Western Blot

Journal: PLoS Pathogens

Article Title: Poly(ADP-ribose) polymerase 1 is necessary for coactivating hypoxia-inducible factor-1-dependent gene expression by Epstein-Barr virus latent membrane protein 1

doi: 10.1371/journal.ppat.1007394

Figure Lengend Snippet: A) Heatmap showing HIF-1α targets that are induced in LMP1+ cells vs LMP1- cells and decreased with PARP inhibition (FDR<0.01 log 2 I1I Fold Change). Gene expression is plotted as z-score normalized FPKM values. B) Validation of targets identified through RNA seq of olaparib-treated samples- qRT-PCR showing relative expression of transcripts in untreated and olaparib-treated LMP1+ cells vs untreated LMP1- cells. C) Lentiviral sh-PARP1-GFP was used to validate olaparib-treated samples. Fluorescent microscopy showing GFP expression after transduction with shControl and shPARP1 following cell sorting by FACS. D) Western blot showing knockdown of PARP1 in LMP1+ cells following lentiviral transduction with shPARP1. E) Validation of targets identified through RNA seq of olaparib-treated samples using shPARP1 cells. qRT-PCR showing relative expression of transcripts in GFP control and shPARP1 LMP1+ cells vs GFP control LMP1- cells. All RT-qPCR Expression is relative to 18s. The graphs are representative of three independent experiments and shows mean ± standard deviation.

Article Snippet: DG75 cells were infected with two separate lentivirus expressing shPARP1 (Origene TR315488A-B), or the sh control vector freshly generated from 293T cells.

Techniques: Inhibition, Expressing, RNA Sequencing Assay, Quantitative RT-PCR, Microscopy, Transduction, FACS, Western Blot, Standard Deviation

Journal: Head & neck

Article Title: PARP1 as a potential therapeutic target in Merkel cell carcinoma

doi: 10.1002/hed.25146

Figure Lengend Snippet: Prevalence of IHC markers of interest

Article Snippet: Immunohistochemistry Immunohistochemical (IHC) analysis for PARP1 (LSBio, clone A6.4.12) was performed in 4 micron paraffin embedded tissue sections using BOND MAX IHC staining protocol by Vision Biosystems platform.

Techniques: Immunohistochemistry